- Home
- ZGM vs NRSN Comparison
ZGM vs NRSN Comparison
Compare ZGM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZGM | NRSN |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Macau | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 29.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZGM | NRSN |
|---|---|---|
| Price | $2.73 | $0.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 39.1K | ★ 489.0K |
| Earning Date | 01-06-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 401.52 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $3,620,780.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | ★ 211.78 | N/A |
| 52 Week Low | $1.90 | $0.81 |
| 52 Week High | $4.51 | $2.60 |
Technical Indicators
Market Signals| Indicator | ZGM | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.38 |
| Support Level | N/A | $0.86 |
| Resistance Level | N/A | $1.24 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 7.89 |
Price Performance
Historical ComparisonAbout ZGM Zenta Group Company Limited Ordinary Shares
Zenta Group Co Ltd is engaged in the provision of industrial park consultation services, business investment consultation services to clients through LIC, and sales of fintech products and services through LFT. Its industrial park consultation services are focused on the pre-development stage. Its business investment consultation services, offered through LIC, mainly focus on assisting clients to acquire stakes in specific investments, and it's normally in the form of equity ownership.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.